RASI Antibody

What is the Renin-Angiotensin System (RAS) and how do RAS inhibitors function?

The Renin-Angiotensin System is a hormone system that regulates blood pressure, fluid balance, and vascular resistance. RAS inhibitors (RASi) work by blocking different components of this pathway. These include angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and direct renin inhibitors. Their primary mechanism involves preventing the formation or action of angiotensin II, a potent vasoconstrictor. In research contexts, RASi are studied not only for their antihypertensive effects but also for their potential influence on immune responses and tumor microenvironments .

What is the connection between ACE2 and RAS inhibitors in the context of viral infections?

Angiotensin-converting enzyme 2 (ACE2) has been identified as a cell entry receptor for certain coronaviruses, including SARS-CoV-2. This has raised questions about whether RAS inhibitors might affect ACE2 expression and consequently influence viral infection risk. Research has investigated whether patients with hypertension should discontinue RASi therapy during COVID-19. A retrospective study of 27 COVID-19 patients with hypertension found no statistically significant differences in clinical symptoms and laboratory tests between patients treated with RASI (14 patients) and those without RASI treatment (13 patients) . The study concluded that RASI could be deemed safe and effective for controlling high blood pressure in COVID-19 patients, though larger sample sizes were recommended for further investigation .

How are antibodies used to study the RAS network?

Antibodies are critical tools for studying the RAS network and its components. The National Cancer Institute's RAS Initiative has developed 104 monoclonal antibodies (mAbs) enabling detection of 27 phosphopeptides and 69 unmodified peptides from 20 proteins in the RAS network . These antibodies have been validated for use in various applications, including Western blotting, immunoprecipitation, protein array, immunohistochemistry, and targeted mass spectrometry. These reagents help researchers measure expression changes and discern pathways in the RAS signaling network .

How do RAS inhibitors impact the efficacy of immunotherapy antibodies in cancer treatment?

This effect appears to be specific to RAS inhibition rather than general blood pressure control, as calcium channel blocker (CCB) use was not significantly associated with improved PFS . The proposed mechanism involves RASi improving the tumor immune microenvironment, as the Renin-Angiotensin system has been shown to induce immunosuppression in tumor microenvironments .

What are the current challenges in validating antibodies for RAS pathway proteins?

Antibody validation for RAS pathway proteins faces several challenges. First, many commercial antibodies lack rigorous validation - a study evaluating 22 commercially available anti-RAS antibodies found that some did not adequately recognize their intended target or showed greater selectivity for another target . Second, application-specific validation is crucial, as some antibodies may work for Western blotting but not for immunofluorescence or immunohistochemical analyses .

The most robust validation approach uses CRISPR knockout (KO) cells as controls. This method has proven more reliable than orthogonal approaches, particularly for immunofluorescence applications. While 80% of antibodies recommended for Western blotting based on orthogonal strategies could detect their intended target, only 38% of antibodies recommended for immunofluorescence based on orthogonal approaches were confirmed when tested with KO controls . The cost of generating custom KO cell lines (estimated at $25,000) significantly exceeds the typical sales of most antibody products (<$5,000), creating economic barriers to comprehensive validation .

How do autoantibodies in the RAS pathway contribute to autoimmune conditions like rheumatoid arthritis?

While the search results don't directly address RAS-specific autoantibodies in rheumatoid arthritis (RA), they do provide context about autoantibodies in RA generally. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) are classical serological markers for RA diagnosis. RF targets the Fc-fragment of IgG and has a specificity of approximately 85% and sensitivity between 60-90% . Anti-CCP belongs to anticitrullinated protein antibodies (ACPAs) and has a sensitivity of 67% and specificity of 95% .

These autoantibodies contribute to RA pathogenesis through various mechanisms, including promoting innate immune cell binding, complement system activation, neutrophil extracellular trap formation, and osteoclast activation . Research into novel autoantibodies, such as anticitrullinated SR-A peptide antibodies, continues to improve diagnostic capabilities .

What are the best practices for selecting cell lines when validating antibodies for RAS pathway research?

When validating antibodies for RAS pathway research, selection of appropriate cell lines is critical. Best practices include:

• Expression level assessment: Select cell lines with detectable levels of the target protein, typically using a threshold of log₂(TPM +1) for RNA expression levels .

• Prioritize amenable cell lines: Focus on cell line backgrounds that:

  • Have short doubling times

  • Are amenable to CRISPR-Cas9 technology

  • Represent different cell/tissue types

Among the eight commonly prioritized cell lines for antibody validation studies are MCF-10A, BxPC-3, A549, NCI-H1792, HeLa, and HEK293 cells, which were used in 62 out of 65 antibody characterization studies in one large-scale validation effort .

• Create proper controls: Generate or obtain knockout (KO) versions of selected cell lines for the most rigorous validation results .

How should researchers evaluate the specificity and sensitivity of antibodies targeting RAS pathway components?

Evaluation of antibody specificity and sensitivity for RAS pathway components should involve:

• Application-specific testing: Test antibodies in all intended applications (Western blot, immunoprecipitation, immunofluorescence) regardless of manufacturer recommendations .

• Side-by-side comparison: Test all available antibodies simultaneously in parental and knockout cell lines using standardized protocols .

• Validation strategy comparison: Genetic approaches (using KO or knockdown samples) provide more reliable validation than orthogonal approaches (which rely on known information about the target). For immunofluorescence applications, genetic validation strategies have been shown to be particularly important, with 80% confirmation rate versus 38% for orthogonal validation methods .

• Documentation and reporting: Document validation data comprehensively, including:

  • Cell lines used and their expression levels

  • Validation methodology

  • Application-specific performance

  • Potential cross-reactivity

The data should be made publicly available through repositories like ZENODO, the Antibody Registry, and manufacturer websites .

What protocols are recommended for studying interactions between RASi and antibody-based immunotherapies?

Based on the retrospective study analyzing the impact of RASi on anti-PD-1/PD-L1 antibody efficacy, the following methodological considerations are important:

What are the recommended quality control measures for antibodies used in RAS pathway research?

Quality control measures for antibodies in RAS pathway research should include:

• Batch testing: Each antibody batch should be validated to ensure consistency.

• Application-specific validation: Validate antibodies specifically for each application (WB, IP, IF) using appropriate positive and negative controls.

• Cross-reactivity assessment: Test for potential cross-reactivity with closely related proteins, particularly for the different RAS isoforms which share high sequence homology .

• Validation using genetic controls: Use CRISPR knockout cell lines as the gold standard for validation rather than relying solely on orthogonal approaches .

• Documentation and traceability:

  • Assign Research Resource Identification (RRID) to each antibody

  • Document all validation experiments and raw data

  • Make validation data publicly accessible through repositories like ZENODO

• Standardized protocols: Develop and follow standardized protocols for each application to ensure reproducibility across different laboratories .